Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority claimed from PCT/US1991/005396external-prioritypatent/WO1992002246A1/en
Publication of CA2089143A1publicationCriticalpatent/CA2089143A1/en
Application grantedgrantedCritical
Publication of CA2089143CpublicationCriticalpatent/CA2089143C/en
The invention in growth factor compositions includes: a novel compound which is a separate pure nicked or pure non-nicked species of epidermal growth factor EGF1-48 or its hEGF1-47 or hEGF1-49 congener compound, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition in dosage form comprising an effective amount of the novel compound; and use thereof for treating abnormal cell growth conditions including gastrointestinal/duodenal lesions; and methods of mak-ing the pure hEGF species. This unique therapeutic utility is enhanced by the unexpected and heretofore unappreciated structural stability and resistance of the pure species to enzymatic degradation.
CA002089143A1990-08-021991-07-30Growth factor compositions, preparation and use
Expired - Fee RelatedCA2089143C
(en)
Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient